Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: A post hoc analysis of the CIBIS-III trial

European Journal of Heart Failure

Volumn 13, Issue 7, 2011, Pages 765-772

  Funck Brentano, Christian ^a,b,c   Van Veldhuisen, Dirk J ^d   Van De Ven, Louis L M ^e   Follath, Ferenc ^f   Goulder, Michael ^g   Willenheimer, Ronnie ^h,i  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f KLINIK IM PARK   (Switzerland)

^g Worldwide Clinical Trials   (United Kingdom)

^h LUND UNIVERSITY   (Sweden)

ⁱ Heart Health Group   (Sweden)

Author keywords

Adrenergic beta antagonists administration and dosage; Angiotensin converting enzyme inhibitors administration and dosage; Doseresponse relationship; Drug; Heart failure drug therapy; Risk factors; Treatment outcome

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

AGED; AGING; ARTICLE; ASTHENIA; BODY WEIGHT; BRADYCARDIA; COUGHING; CREATININE BLOOD LEVEL; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DYSPNEA; FATIGUE; FEMALE; HEART FAILURE; HEART VENTRICLE EXTRASYSTOLE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PAROXYSMAL DYSPNEA; PERIPHERAL EDEMA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BISOPROLOL; ENALAPRIL; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; MALE; MULTIVARIATE ANALYSIS; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 79959978534     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr051     Document Type: Article

References (16)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
2. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE Inhibitor Trials. JAMA 1995;273:1450-1456.
3. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
4. MERIT-HF Study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
5. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658. (Pubitemid 32479962)
6. Willenheimer R, Erdmann E, Follath F, Krum H, Ponikowski P, Silke B, Van Veldhuisen DJ, Van De Ven L, Verkenne P, Lechat P. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. Eur J Heart Fail 2004;6:493-500. (Pubitemid 38746594)
7. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112: 2426-2435. (Pubitemid 41504492)
8. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update incorporated into the ACC/ AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90.
9. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94: 2807-2816. (Pubitemid 26411745)
10. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF, ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100: 2312-2318.
11. Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, Jaillon P. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). Eur Heart J 2003; 24:552-559. (Pubitemid 36343101)
12. Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, Wedel H. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40: 491-498. (Pubitemid 34833165)
13. Dobre D, van Veldhuisen DJ, Mordenti G, Vintila M, Haaijer-Ruskamp FM, Coats AJ, Poole-Wilson PA, Flather MD. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J 2007; 154:109-115. (Pubitemid 46920477)
14. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374:1840-1848.
15. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784-794.
16. Krum H, Van Veldhuisen DJ, Funck-Brentano C, Vanoli E, Silke B, Erdmann E, Follath F, Ponikowski P, Goulder M, Meyer W, Lechat P, Willenheimer R. Effect on mode of death of heart failure treatment started with bisoprolol followed by enalapril, compared to the opposite order: results of the Randomized CIBIS III Trial. Cardiovasc Ther 2010;9:9.